Search results for "FeGa"
showing 10 items of 10 documents
Injectable Hydrogel for Synergetic Low Dose Radiotherapy, Chemodynamic Therapy and Photothermal Therapy
2021
Higher doses of radiotherapy (RT) are associated with resistance induction, therefore highly selective and controllable radiosensitizers are urgently needed. To address this issue, we developed a FeGA-based injectable hydrogel system (FH) that can be used in combination with low-dose radiation. Our FH can deliver FeGA directly to the tumor site via intratumoral injection, where it is a reservoir-based system to conserve FeGA. The photothermal properties of FeGA steadily dissolve FH under laser irradiation, and, simultaneously, FeGA reacts with a large amount of H2O2 in the cell to produce OH (Fenton reaction) which is highly toxic to mitochondria, rendering the cell inactive and reducing ra…
MARCATORI BIOMOLECOLARI NELLE MALATTIE CRONICHE DEL FEGATO : IMPLICAZIONI DIAGNOSTICHE E TERAPEUTICHE
2011
Trapianto di fegato per epatocarcinoma (HCC): integrazione di criteri clinici e radiologici con indicatori biologici per l’identificazione di pazient…
2011
EPATOMI MALIGNI DEL BAMBINO
1991
I tumori magli del fegato in età pediatrica sono rappresentati da due forme istologiche differenti: l'Epatoblastoma (EPB) e l'Epatocarcinoma (EPC). Gli Autori esaminano le caratteristiche cliniche, la stadiazione e gli aspetti terapeutici. Vengono altresì presentati i dati della letteratura ed i risultati del Protocollo Italiano di cura di queste neoplasie.
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy
2011
A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…